Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide.

Safety and tolerability of medications approved for chronic weight management.

Obesity impairs γδ T cell homeostasis and antiviral function in humans.

Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial.

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.

Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm.

The effect of leptin, caffeine/ephedrine, and their combination upon visceral fat mass and weight loss.

The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity.